Evotec stock falls 3.57 percent after leadership change

Published on 10/03/2026 at 22:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock was last quoted at EUR 2.920 on Xetra on October 2, 2026. Berenberg kept its EUR 3.60 target, while H1 revenue fell 19.2 percent to EUR 300.1 million.

Bunte Pop-Art-Comic-Illustration eines Wissenschaftlers mit leuchtendem Reagenzglas im Labor — Pop-Art-Comic-Szene mit Wissenschaftler und Reagenzglas symbolisiert lebendig die Forschungswelt von Evotec SE, ISIN DE0005664809, Illustration mit AI erstellt.

Evotec stock (ISIN DE0005664809) was last quoted at EUR 2.920 on Xetra on October 2, 2026, down 3.57 percent from the previous session. The latest corporate catalyst is a change at the top of Evotec's scientific organization, with Chief Scientific Officer Cord Dohrmann leaving effective September 30, 2026.

Leadership change tests the strategy

According to PR Newswire on September 29, 2026, Dohrmann and Evotec agreed on his departure by mutual consent. He had served as chief scientific officer and a management board member since 2010, and the company has started searching for a successor.

The transition arrives during a broader commercial reset. Evotec's technology platform remains central to its drug discovery, biologics and cell therapy activities, but the financial figures place execution ahead of scientific positioning in the near term.

Revenue fell 19.2 percent

Evotec generated EUR 300.1 million in group revenue during the first half of 2026, a 19.2 percent year-over-year decline. In the second quarter, revenue reached EUR 143.5 million, down 16.2 percent from EUR 171.2 million a year earlier, while net income was negative EUR 46.6 million, according to Nadiralpha in its Q2 2026 results review.

The company guides for full-year 2026 revenue of EUR 570 million to EUR 610 million, compared with the earlier range of EUR 700 million to EUR 780 million. Adjusted EBITDA guidance shifted from EUR 0 million to EUR 40 million of income to a loss of EUR 70 million to EUR 105 million, making revenue conversion and cost control the key financial tests for the remaining year.

Berenberg keeps EUR 3.60 target

Berenberg maintained its Hold rating and a EUR 3.60 price target after a discussion with CEO Christian Wojczewski, according to Finanznachrichten on September 24, 2026. Analyst Christian Ehmann cited commercial repositioning and delayed milestones as factors that reduce the predictability of revenue development.

Third quarter report has a date

Evotec is scheduled to publish its third-quarter report on November 5, 2026, according to Boerse Express. That report will give investors a new operating checkpoint after the H1 revenue decline and the reduced full-year outlook.

Evotec stock stays below EUR 3

At EUR 2.920 on Xetra on October 2, 2026, Evotec stock was down 3.57 percent for the session. The combination of a leadership transition, lower revenue guidance and the November reporting date leaves execution evidence as the next measurable test for the shares.